Arcutis Biotherapeutics, Inc. (ARQT) Form 8-K — Oct 28, 2026
$ARQTForm 8-KItems 5.02, 7.01, 9.01Filed Oct 28, 2026, 9:04 AM ET0001628280-26-067752Original filing
Arcutis Biotherapeutics (Nasdaq: ARQT) appointed Dr. Rob Scott to its Board of Directors effective October 23, 2026, expanding the Board from ten to eleven members. Dr. Scott joins as an independent Class II director and a member of the Nominating and Corporate Governance Committee.
Key figures
- Director age
- 73
- Director class
- Class II, term expiring 2028 annual meeting
- Board size before
- 10
- Committee retainer usd
- 5000
- Initial stock option shares
- 20507
- Annual cash retainer board usd
- 50000
- Prorated annual equity award usd
- 350000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.